Stars Align for Merger Between US and European Online Wellness Giants, Ingenio and adviqo
2.5.2022 20:13:00 EEST | Business Wire | Press release
Ingenio, LLC (“Ingenio”), a portfolio company of Alpine Investors, and the owner of North America’s largest online marketplace and media platform focused on spiritual and emotional wellness, has acquired its largest European peer, adviqo Group (“adviqo”).
The transaction creates the global leader in this fast-growing segment of the media and technology sector, combining Ingenio’s 12 brands, which include Keen.com, Purple Garden, Horoscope.com and Astrology.com, with adviqo’s 19 brands, which feature Questico, Horoskop.de, and Kang.
Since being founded, the two companies have facilitated over 180 million consultations between customers and advisors (counselors, coaches, guides and spiritualists).
Furthermore, Ingenio owns and operates one of the world’s largest astrology media companies. Its four media brands reach over 20 million people monthly. Meanwhile, adviqo reaches over 36 million households through its TV broadcasts, in addition to its digital platforms. The combined media businesses will offer customers the largest global collection of astrology content.
During the Covid-19 pandemic Ingenio saw a surge in users across its platforms, as people – and especially millennials – increasingly turned to technology to connect more meaningfully and conveniently. This was reflected in Ingenio’s customer base which grew 30% since the start of the pandemic. In anticipation of its strong growth prospects, Ingenio recently appointed Kirstin Hoefer as Keen.com’s first Brand President. She will be responsible for leading and driving top-line growth and product innovation.
Warren Heffelfinger, CEO of San Francisco-headquartered Ingenio, said: “This deal represents a major milestone in unlocking our next stage of growth. We will be stronger together as we explore opportunities to expand into new markets, drive innovation, and sharpen our focus on personal wellness.
“The combination of our leading businesses brings clear benefits to all stakeholders. As we pursue our joint vision of becoming the global leader in personal guidance, life advice and wellness, customers will see improved products and services provided by a broader, wellness-related product portfolio tailored to their needs. Our advisors will benefit from enhanced features and greater resource support, access to a broader consumer base, and accelerated revenue growth. Employees will also have access to more global career paths. Importantly, both companies are aligned around a mutual commitment to empower people to live happier lives.
“I’d like to thank all our employees for their hard work over many years to help us reach this point. We have exciting prospects ahead, along with stability of ownership and management, and we continue to attract new high-quality investors like Apollo, a blue-chip alternative asset manager.”
Bryan Leppi, Co-founder and Chief Business Development Officer for Berlin-based adviqo, added: “Ingenio and adviqo are leaders in our respective regions. With little geographical crossover we offer complementary product suites featuring online marketplaces, websites and apps, streaming media and podcasts, content-based online offers, as well as TV and magazines. So, together, we are creating a comprehensive and global market leader.
“While there is a strong business case for this combination, having shared values and attitudes, and the opportunity to learn from each other, is equally important for the longterm success of our combined group. This will allow us to tap into new products and markets and to further develop our skill sets like never before. We are excited about what the future holds.”
About Ingenio
Ingenio is the market leader in spiritual and emotional guidance in the US. Headquartered in San Francisco, CA, Ingenio is a collection of online destinations including Keen.com and Purple Garden, where people find emotional and spiritual guidance on love, relationships, and life. With a team of more than 140 colleagues, Ingenio is passionate about continuous improvement and connecting people with the best content and advisors to empower them to live happier lives.
Ingenio also owns and operates one of the world’s largest astrology media companies, with brands including Horoscope.com, Astrology.com, Horoscopo.com and SunSigns.com. They reach more than 20 million unique users each month and publish daily content via the four websites, 39 email newsletters, and three mobile apps.
About adviqo
adviqo is the market leader in spiritual and emotional guidance in Europe, with headquarters in Berlin, Germany. It employs more than 240 people worldwide, including Germany, France, Italy, Spain and the UK.
adviqo’s mission is to provide person-to-person advice and inspiring content to anyone searching for self-care, personal growth and clarity. Its portfolio includes websites and apps, streaming media and podcasts, content-based online offerings, TV and magazines. adviqo operates leading brands including Questico, The Circle, Kang, Horoskop.de, viversum and Zodiac Touch.
About Alpine Investors
Alpine Investors is a people-driven private equity firm that is committed to building enduring companies by working with, learning from, and developing exceptional people. Alpine specializes in investments in companies in the software and services industries. Its PeopleFirst strategy includes a CEO program that allows Alpine to bring leadership to situations where additional or new management is needed post-transaction. Alpine is currently investing out of its $2.25 billion eighth fund.
For more information, visit http://www.alpineinvestors.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005194/en/
Contact information
Media contacts
MC Brand Communications (USA)
Flerine Cruz
flerine@mcbrandcommunications.com
(919) 257-8818
Maitland/amo (Europe) ingenio@maitland.co.uk
+44 (0) 207 379 5151
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
